Filing Flows › Recursion Pharmaceuticals (RXRX) › Q2 2025
Recursion Pharmaceuticals (RXRX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Recursion Pharmaceuticals (RXRX) reported revenue of $19.2M for the second quarter 2025 (Q2 2025), +33% from a year earlier and +30% from the quarter before. Operating margin was -916.8%, net loss $172M (894.2% of revenue).
Recursion Pharmaceuticals, Q2 2025: revenue $19.2M (+33% year over year), operating margin -916.8%, net loss $172M, operating cash flow −$76.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.2M | +30% | +33% |
| Operating profit | −$176M | — | — |
| Net earnings | −$172M | — | — |
| Operating cash flow | −$76.4M | — | — |
What changed
Revenue was $19.2M in Q2 2025, up 33% year over year and up 30% from the previous quarter. Operating revenue was the largest line at 99% of revenue. Operating revenue added $4.7M year over year (up 33%), 98% of the total change.
Operating costs exceeded revenue by $176.2M, an operating margin of -916.8%. Total costs grew 70% against revenue growth of 33%. The fastest-growing cost line was Cost of revenue (+119%). The quarter ended with a net loss of $171.9M, narrower than the previous quarter's $202.5M loss.
Operating cash flow was −$76.4M. Non-cash charges added back $23.8M of depreciation and amortization and $26.2M of share-based compensation. Working capital and other items added $45.5M. Capital expenditures of $3.1M exceeded it, leaving free cash flow of −$79.6M.
Questions
What was Recursion Pharmaceuticals' revenue in the second quarter 2025?
Recursion Pharmaceuticals (RXRX) reported revenue of $19.2M for the second quarter 2025 (Q2 2025), +33% from a year earlier and +30% from the quarter before.
Was Recursion Pharmaceuticals profitable in the second quarter 2025?
Operating loss was $176M (-916.8% of revenue) and net loss $172M.